
a
n = 10 (100 mg)
n = 12 (300 mg)
n = 10 (100 mg)
n = 12 (300 mg)
n = 10 (100 mg)
n = 11 (300 mg)
n = 1 (100 mg)
n = 10 (300 mg)
Change in iAUC60 from baseline (%)
80
60
40
20
0
-20
-40
-60
2
8
29
57
Study day
Vandetanib 100 mg:
Individual patient
Vandetanib 300 mg:
Individual patient


b
n = 10 (100 mg)
n = 12 (300 mg)
n = 10 (100 mg)
n = 12 (300 mg)
n = 10 (100 mg)
n = 11 (300 mg)
n = 1 (100 mg)
n = 10 (300 mg)
Change in Ktrans from baseline (%)
200
150
100
50
0
-50
-100
2
8
29
57
Study day
Vandetanib 100 mg:
Individual patient
Vandetanib 300 mg:
Individual patient


c
n = 9 (100 mg)
n = 12 (300 mg)
n = 10 (100 mg)
n = 11 (300 mg)
n = 10 (100 mg)
n = 11 (300 mg)
n = 1 (100 mg)
n = 10 (300 mg)
Mean change in T2* from baseline (%)
60
40
20
0
-20
-40
2
8
29
57
Study day
Vandetanib 100 mg:
Individual patient
Vandetanib 300 mg:
Individual patient